AppLovin NASDAQ: APP stock has had an incredible uptick in 2024, with shares over quadrupling in value. Despite its massive rise, Wall Street analysts are still projecting upside in the tech stock.
Besides Wall Street's top -and-bottom-line estimates for AppLovin (APP), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
The latest trading day saw AppLovin (APP) settling at $171.65, representing a -0.34% change from its previous close.
AppLovin (APP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
AppLovin (APP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here is how AppLovin (APP) and Distribution Solutions Group (DSGR) have performed compared to their sector so far this year.
AppLovin Corp (NASDAQ: APP) continues its remarkable ascent, hitting new all-time highs daily, including a peak of $163.13 yesterday. On October 22, Loop Capital initiated coverage on the stock with a ‘Buy' rating and a $181 price target.
AppLovin (APP) reachead $158.95 at the closing of the latest trading day, reflecting a +0.06% change compared to its last close.
Strong earnings growth and a crucial place in its industry have shares of mobile marketer AppLovin, Corp. (APP).
AppLovin (APP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
AppLovin's impressive growth is driven by AI-related tailwinds and positive fundamentals, but the current stock price appears to be too pricey, warranting a "Hold" rating. Q2 financials show strong revenue and EPS growth, but potential peak EBITDA margins and declining monthly active payers raise concerns. Despite a solid balance sheet and good shareholder returns, valuation analysis suggests the stock is overvalued by 10-11% based on current consensus.